Summary The development of cervical carcinoma is strongly associated with specific types of human papillomaviruses (HPVs). A role for cellular immunity in cervical disease is supported by the increased occurrence of HPV-associated lesions in immunosuppressed individuals. Upon viral infection or malignant transformation, ensuing alterations in gene expression result in the generation of novel sets of peptides which can form complexes with specific HLA class I heavy chains and P2-microglobulin. These are then expressed at the cell surface as potential targets for specific T cells. In this study of 100 carcinomas HLA-A and -B class I expression by the tumour cells was down-regulated at one or more alleles in at least 73% of cervical carcinomas. Interference with the transporter associated with antigen presentation (TAP), which translocates cytosolic peptides from endogenously synthesised proteins (e.g. viral) into the lumen of the endoplasmic reticulum was found in 38% of the HLA class I down-regulated tumours. Loss of expression for common HLA class I alleles ranged from 36% to 71%, and such changes might be expected to influence specific immunogenic peptide presentation and consequent immune recognition. These results underline the importance of single as well as multiple allelic loss in cervical neoplasia and have important implications for attempts to intervene immunologically in cervical cancer.
The development of carcinoma of the cervix is strongly associated with certain high-risk human papillomaviruses (Niedobitek and Herbst, 1991; Munoz et al., 1992) , and the E6 and E7 oncogenes that are frequently retained by the tumour cells are believed to play a necessary role in the tumorigenesis (Smotkin and Wettstein, 1987; DiMaio, 1991) . A role for the immune response in cervical neoplasia is supported by the increased occurrence of HPV-associated cervical lesions in immunosuppressed individuals (Laga et al., 1992; Schneider and Koutsky, 1992) . The immunological recognition of viral antigens by T cells is restricted by the HLA class I polymorphic products of the major histocompatibility complex (MHC). Following translation, class I heavy chain and P2-microglobulin molecules are translocated to the lumen of the endoplasmic reticulum (ER) and bind allele-compatible peptides (usually nonamers) (Bjorkman et al., 1987; Monaco, 1992) . These peptides are generated from endogenously synthesised proteins (e.g. virus) in the cytoplasm, possibly by the proteasome (Goldberg and Rock, 1992) . The peptides are transported to the lumen of the ER via a specific ABC-type transporter associated with antigen processing (TAP), which is composed of TAP-1 and -2 subunits encoded by genes in the MHC (Trowsdale et al., 1990; Kelly et al., 1992) . When peptides bind to specific HLA heavy chains there are conformational changes which are probably stabilised by the binding of P2-microglobulin molecules . In the absence of appropriate peptide, heavy chain may associate with p2-microglobulin, but the complex is not stable and is unlikely to be expressed at the surface (Townsend et al., 1989; Baas et al., 1992) . It is the heavy chain-P2-microglobulin-peptide complexes which are the potential targets for immune surveillance mechanisms mediated by CD8+ cytolytic T cells.
Any virus/disease-related alterations in MHC expression would critically influence immune surveillance of viral infection and have important consequences for the elimination of infected cells. The loss or down-regulation of HLA class I expression in different types of cancers including cervical carcinomas is well documented (Moller and Hammerling, 1992; Garrido et al., 1993; Duggan-Keen et al., 1994) . Most studies have been performed by immunohistochemistry using monoclonal antibodies (MAbs) which recognise either all HLA-A, -B, -C molecules or locus-specific reagents, both of which will fail to detect down-regulation of any individual allelic expression. It is possible that the down-regulation of HLA class I may be the result of immunoselective events, advantageous to the evolution of an invasive cancer. If this were true then it follows that those HLA allelic products capable of presenting target peptides, for example HPV 16 E6/E7, would be preferentially lost. This phenotype could be produced as a result of interference at any level in the regulation of expression of HLA . Thus, the tumours with an HLA class I downregulated phenotype could be very heterogeneous in their defects. TAP function appears to be one important factor in the observed down-regulation of HLA class I expression in cervical cancer, but it is not known what proportion of the observed losses may result from this mechanism (Cromme et al., 1994a,b One hundred cervical cancers (94 squamous cell carcinomas, five adenosquamous/adenocarcinoma and one anaplastic tumour) were obtained consecutively from one operating list from women attending the Christie Hospital, Manchester, UK. With informed consent, blood was collected preoperatively and biopsies were taken at the time of surgical staging before treatment with radiotherapy. In addition, seven specimens of normal cervix were taken from women undergoing elective hysterectomy for benign conditions and in whom only previous normal cervical smears were documented. The mean age for the group of 100 patients was 52.8 years with a range of 25-85 years. The distribution of stage determined at the time of radiotherapy was: stage I, 22; stage II, 40; stage III, 35; stage IV, 3. The incidence of HPV detection in these tumours was 74.1% HPV 16 (including three cases with HPV 16 and 18), 23.5% other HPV types (including 11, 1.2%; 18, 11.6%,; 31, 1.2%; 33, 2.3% and X, 7.0%) and 2.4% HPV negative, determined as previously described (Van de Brule et al., 1990 ).
Immunohistochemistry
Allelic expression was determined using the patient HLA class I tissue type (Glew et al., 1993a) and immunohistochemistry performed on 71am sections from snap-fro4en tumour biopsies with a set of HLA-specific MAbs (Connor and Stern, 1990) . The tumour tissue was identified using a MAb, CK-1 (LP34 clone, Dako), recognising epithelial cytokeratins 6 and 18. In consecutive sections the following primary MAbs were used: W6/32 (monomorphic HLA class I), HC1O (HLA-B and -C locus), BM63 (02-microglobulin), HB82 (HLA-A2), GAP-A3 (HLA-A3), BB7.1 (HLA-B7), 116/5/28 (HLA-Bw4) and 126/30 (HLA-Bw6). Additional antigen-specific IgM monoclonal antibodies were provided by One Lambda (Canoga Park, CA, USA) and validated on at least six different tissue typed sections. In all sections normal stromal tissue was present and staining for class I was confirmed by using MAb W6/32. Only MAbs which stained for the antigen of their specificity and that did not label sections with other tissue types were used in this study. MAbs H41 (HLA-A9), H213 (HLA-A26), H173 (HLA-A30,31), H135A (HLA-A32), 404HA-1 (HLA-B8), H66 (HLA-B12), 21 1BHA-1 (HLA-B13) and H47 (HLA-B18) were used in a three-step technique with avidin-biotin complex/horseradish peroxidase (Dako). A polyclonal rabbit antiserum against the TAP-1 protein was used as previously described (Cromme et al., 1994a) .
Slides were read by two independent observers and scored '+ +' if all tumour cells stained with similar intensity to the surrounding stroma, '+' if all tumour cells stained but the intensity was clearly weak in comparison with the stroma, '±' if there were clear negatively staining areas within the tumour usually constituting between 25% and 75% of the total area and '-' where none of the tumour cells stained. For the purpose of analysis '+ +' and '+' were treated as normal expression and '±' and '-' as down-regulated.
Where MAb W6/32 (pan-HLA class I) showed loss of staining, all alleles were scored as down-regulated (-) unless discrepancies with allele-specific MAbs were found (see Results). When W6/32 scored positive, individual alleles were scored as unknown (?) unless specific MAbs could show that the tumour cells expressed the allele. HLA-B locus expression was further defined by the use of the HCIO MAb (HLA-B, -C locus specific) and HLA-Bw4-and -Bw6-specific MAbs, the last two reagents defining exclusive groups of HLA-B antigens (Bodmer et al., 1991) . The HLA-A25, -A32 crosssections of the Bw4 MAb were taken into account when interpreting the data. In one case in this series such a crossreaction was evident by immunohistochemistry but the phenotype was confirmed using the HLA-A32 MAb. All inferred expression using group-or locus-specific MAbs was confirmed with allele-specific MAbs if they were available so that each specimen was examined with 7-11 MAbs on consecutive sections.
Results
In the seven normal cervical biopsies, expression was normal in each of the 20/28 HLA alleles whose expression could be determined. The staining was associated with the deep (basal) layers, the area from which premalignant lesions originate (Stanley, 1994) , with variation in intensity of staining in the middle and upper two-thirds, as described previously (Glew et al., 1993b) .
By contrast, complete or heterogeneous loss of HLA expression was found at one or more alleles in 73% of tumour specimens. This constituted 30%, 38%, 10% and 22% observed loss at one, two, three or four alleles of HLA-A and -B (Table I) . This is a minimum estimate since 20/27 other cases had unknown HLA-A or -B allelic expression. ?   32  32  32  2  33  33  11  11  3  2  28  2  0  26  33  3  11  31  32  32  0  0  3 4  4  2  2  2  2  2  2  2  3  3  3  3  3  3  3  3  3  3  4  4  4  4  4  2  2  2  2  2  2  2  2  2  3  3  3  3  3  3  3  3  3  3  3  4  4  4 (Figure 1 ). In nine specimens loss defined by the locus-specific reagents was not confirmed by the allele-specific MAbs. The specific alleles expressed by specimens 76 (HLA-A23, -A32), 82 (HLA-A3), 60 (HLA-B8) and 74 (HLA-A30, -B18) occurred even though there was altered W6/32 reactivity. With HC10 indicating down-regulation, the following specimens had specific allelic expression: 49 (HLA-B44), 64 (HLA-B44), 65 (HLA-B62), 59 (HLA-B7) and 18 (HLA-B7). The last two cases can be explained by HCI0 not recognising when complexed to P2-microglobulin (Gillet et al., 1990) . The remaining seven discrepancies cannot be explained by known differences in the ability of the MAbs to detect individual HLA antigens, but these may exist. In 7/9 of these cases, locus-specific MAb staining was heterogeneous; this might reflect low levels of HLA expression which was better detected by the allele-specific MAb. Anti-P2-microglobulin labelling was identical to W6/32 in all but two cases, which probably exhibited only HLA-C expression. Down-regulation of HLA-C expression could only be inferred from the HC10-negative specimens; no HLA-C allele showed altered frequency in this group. Table II documents the frequency of individual HLA antigens in the patients, the proportions of tumours in which expression could be determined (304/400 HLA-A or -B alleles) and their HLA phenotypes as well as the proportion of down-regulation for each allele. The mean incidence of antigen down-regulation was 53%, and in patients in whom individual antigens are represented in ten or more specimens, the frequency ranges between 36% and 71% (Figure 2) .
One mechanism that would account for the frequent loss of more than one allelic product in a given tumour is interference with the TAP transporter. TAP-1 expression is determined immunohistochemically and analysed in relation to the HLA class I phenotype of the tumours (Table I) . The data indicate a link between TAP-1 and HLA class I expression, since when TAP-1 expression is abnormal there is always some HLA class I loss. Of the 28 specimens with down-regulated TAP-1 expression, 13 show concordant down-regulation of HLA-A, -B, -C and P2-microglobulin and 14 exhibit HLA-B or HLA-B and -C down-regulation. However, HLA class I loss was frequently observed (45 cases) with normal TAP-1 levels as determined immunohistochemically. Table II and Figure 2 show the relationship between TAP-1 and individual antigen expression and indicates that TAP-associated and non-TAP mechanisms may contribute differentially to the overall HLA antigen down-regulation observed. No associations between altered (16. Ioss F.00%) Three alleles los (7.00%) expression of HLA-A, or -B or TAP-1 and HPV type were seen (Table I) .
Clinical staging defines the degree of spread from the primary site of the tumour and is the most important prognostic indicator in cervical cancer. There is a trend for increasing HLA class I loss with disease stage (stage I, II, III, IV have 64%, 81%, 86% and 100% loss respectively) but no correlation is seen with tumour type or degree of differentiation.
Discussion
This study has provided strong evidence for a very high frequency of HLA class I down-regulation in cervical carcinoma. Such loss may allow a tumour to behave more aggressively in the absence of effective immunosurveillance. It is interesting to speculate that these changes are the result of immunoselective influences in the natural history of cervical neoplasia. Indeed, there is evidence of an increased incidence of HLA class I down-regulation in cervical carcinoma lymph node metastases (Cromme et al., 1994b) and at an enhanced frequency for HLA-B7/40 (Honma et al., 1994) . Even the loss of expression of a single MHC restriction element can allow a tumour to grow progressively (Seung et al., 1993) .
The concordance of down-regulation of the TAP-1, HLA class I and P2-microglobulin proteins which occurs in a significant proportion of the cervical carcinomas may result from a coordinate interference with expression of each of the encoding genes, for example at the transcriptional level of regulation. However, given the sequence of events in the peptide-processing pathway, interference with TAP function could produce the observed results in 38% (28/73) of cases. Lack of TAP-1 expression does not interfere with every HLA allele's expression, and this may account for some of the tumours with abnormal TAP expression in which the following allelic expression was detected: HLA-A2, -A3, -A24, -A19, -B7, -B8, -B18 and B62 (Table I ). These exceptions might reflect endogenous peptides present in the ER lumen, for example specific signal peptides which can promote HLA expression in the absence of a function4l transporter (Wei and Cresswell, 1992) .
While there may be a causal relationship between downregulation of TAP-1 and HLA class I expression, it cannot account for all the HLA class I loss observed. Additional non-TAP-associated mechanisms by which the various patterns of HLA expression observed might be explained include loss of one copy of chromosome 6 (Foulkes et al., 1993) or selective down-regulation of the products of either the HLA-A or -B locus . In this study HLA-A and -B locus expression could be completely determined in 33 HLA class I down-regulated cases, and the patterns of ex- Table II ). 0, Normal TAP-1 expression; *, abnormal TAP-1 expression.
I Pruur alldia to pression of HLA-A and -B were consistent with TAP-I particular HLA antigens for which MAbs were available, and associated loss in 18 (55%), loss of a single chromosome 6 in the latter speculative interpretation must be confirmed by three (9%) and selective B locus loss in two (6%). In five more direct molecular analysis. There is evidence for such cases (15%) a loss of expression of a single HLA-A or -B heterogeneity in mechanisms leading to HLA class I downallelic product could be definitively documented, and there regulation in many different cancers (Garrido et al., 1993) , were five others. In the group of 33 patients there was an and this presumably reflects the selection of immunologically over-representation of homozygotes identical at either HLAadvantaged variants during the natural history of the disease. A, HLA-B or HLA-A and -B loci, as well as a bias for
The finding that individual MHC class I alleles are down- (Burrows et al., 1990; Gavioli et al., 1993) , then both down-regulation of expression of that allele and/or the evolution of the pathogen target epitopes (Philips et al., 1991; Hill et al., 1992) will also influence the development and disease progression of cervical cancer. The importance of both HLA type and viral epitope presentation in cervical cancer is emphasised by our recent data which have shown an association between the HLA-B7 genotype and poorer survival experience of cervical cancer patients. It appears that both down-regulation of HLA-B7 (DugganKeen, submitted) and viral heterogeneity (Ellis et al., 1995) may contribute to the HLA-B7 genotype influence on disease outcome.
The viral aetiology of cervical cancer has encouraged the possibility of therapeutic immunisation against the E6 and E7 high-risk HPV oncogene proteins which are frequently retained by the tumour cells (Melief and Kast, 1992; Stauss and Beverley, 1994) . Certainly, the loss of tumour HLA class I expression even at an early stage of disease has profound implications for such immune intervention strategies. Presumably, the tumours have also acquired resistance to the host natural killer effectors which specialise in surveillance of HLA-negative cells . It may be possible to restore HLA expression, for example with interferon treatment (Kopp et al., 1993) , but the heterogeneity in HLA class I loss mechanisms may limit this approach.
